Summary
226.42 -2.59(-1.13%)03/13/2026
Ascendis Pharma A/S (ASND)
ASND reported last earnings on 2025-11-12 after the market. An EPS of $-1.17 was observed compared to an estimated EPS of $-0.41, resulting in a surprise value of $-0.76. A revenue of $250 million was observed compared to an estimated revenue of $303 million, resulting in a surprise value of $-53 Million.
Ascendis Pharma A/S (ASND)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -1.13 | 6.48 | 1.78 | 10.07 | 18.79 | 53.29 | 24.46 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Strong Sell |
| ROE | Strong Buy |
| ROA | Strong Sell |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 226.42 | |
| Open | 230.76 | |
| High | 233.06 | |
| Low | 222.95 | |
| Volume | 526,963 | |
| Change | -2.59 | |
| Change % | -1.13 | |
| Avg Volume (20 Days) | 653,607 | |
| Volume/Avg Volume (20 Days) Ratio | 0.81 | |
| 52 Week Range | 118.03 - 229.94 | |
| Price vs 52 Week High | -1.53% | |
| Price vs 52 Week Low | 91.83% | |
| Range | 0.78 | |
| Gap Up/Down | -1.80 | |
Profitibility | ||
| Market Capitalization (Mln) | 12,044 | |
| Revenue per share | 11.6945 | |
| Net Income per share | -3.7099 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -53.1823 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
03/15 03:30 EST - defenseworld.net
Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND
Ally Bridge Group NY LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ: ASND) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 51,080 shares of the biotechnology company's stock, valued...
Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND
Ally Bridge Group NY LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ: ASND) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 51,080 shares of the biotechnology company's stock, valued...
03/12 12:49 EST - seekingalpha.com
Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity
We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position in Tractor Supply after recent share weakness created a compelling entry point, in our view. Tyler...
Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity
We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position in Tractor Supply after recent share weakness created a compelling entry point, in our view. Tyler...
03/12 04:02 EST - defenseworld.net
Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND
Barometer Capital Management Inc. increased its position in Ascendis Pharma A/S (NASDAQ: ASND) by 288.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,904 shares of the biotechnology...
Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND
Barometer Capital Management Inc. increased its position in Ascendis Pharma A/S (NASDAQ: ASND) by 288.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,904 shares of the biotechnology...
03/10 02:10 EST - defenseworld.net
Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages
Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, sixteen have given a buy recommendation...
Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages
Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, sixteen have given a buy recommendation...
03/04 14:42 EST - seekingalpha.com
Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript
03/03 12:05 EST - seekingalpha.com
Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
Ascendis Pharma secured FDA approval for Yuviwel in achondroplasia, despite ongoing legal challenges from BioMarin. I expect Yuviwel's U.S. sales to be modest, with stronger international growth potential starting next year, but also meaningful competition from BridgeBio's infigratinib. The Yuviwel...
Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
Ascendis Pharma secured FDA approval for Yuviwel in achondroplasia, despite ongoing legal challenges from BioMarin. I expect Yuviwel's U.S. sales to be modest, with stronger international growth potential starting next year, but also meaningful competition from BridgeBio's infigratinib. The Yuviwel...
03/03 03:06 EST - defenseworld.net
American Century Companies Inc. Buys 13,797 Shares of Ascendis Pharma A/S $ASND
American Century Companies Inc. lifted its stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 544,606 shares of the biotechnology company's...
American Century Companies Inc. Buys 13,797 Shares of Ascendis Pharma A/S $ASND
American Century Companies Inc. lifted its stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 544,606 shares of the biotechnology company's...
03/02 16:57 EST - seekingalpha.com
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
03/02 08:43 EST - globenewswire.com
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific...
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific...
03/02 08:02 EST - feeds.benzinga.com
Ascendis Wins FDA Approval For Rare Disease Therapy
Ascendis Pharma shares rise after FDA approves Yuviwel, a weekly treatment for children with achondroplasia.
Ascendis Wins FDA Approval For Rare Disease Therapy
Ascendis Pharma shares rise after FDA approves Yuviwel, a weekly treatment for children with achondroplasia.
02/27 17:57 EST - globenewswire.com
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only...
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only...
02/27 03:16 EST - defenseworld.net
Artisan Partners Limited Partnership Has $739.75 Million Stock Position in Ascendis Pharma A/S $ASND
Artisan Partners Limited Partnership lowered its position in Ascendis Pharma A/S (NASDAQ: ASND) by 6.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,720,880 shares of the biotechnology...
Artisan Partners Limited Partnership Has $739.75 Million Stock Position in Ascendis Pharma A/S $ASND
Artisan Partners Limited Partnership lowered its position in Ascendis Pharma A/S (NASDAQ: ASND) by 6.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,720,880 shares of the biotechnology...
02/12 07:33 EST - seekingalpha.com
Ascendis Pharma FY 2025 Results: More Than A Takeover Story
Ascendis Pharma has transitioned into a revenue-scaled commercial biotech, driven by Yorvipath's rapid adoption and strong FY25 results. ASND's 2025 product revenue surged to €684 million, with Yorvipath accounting for nearly 70% and operating profit turning positive in 4Q25. TransCon CNP's...
Ascendis Pharma FY 2025 Results: More Than A Takeover Story
Ascendis Pharma has transitioned into a revenue-scaled commercial biotech, driven by Yorvipath's rapid adoption and strong FY25 results. ASND's 2025 product revenue surged to €684 million, with Yorvipath accounting for nearly 70% and operating profit turning positive in 4Q25. TransCon CNP's...
02/11 20:24 EST - seekingalpha.com
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
02/11 16:01 EST - globenewswire.com
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
02/04 16:01 EST - globenewswire.com
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to...
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to...
01/20 13:52 EST - gurufocus.com
HARBOR CAPITAL ADVISORS, INC. Sells 269 Shares of Ascendis Pharma AS (ASND)
Summary HARBOR CAPITAL ADVISORS, INC. reduced its stake in Ascendis Pharma AS (ASND) by 1.17%, selling 269 shares and holding 22,734 shares valued at a
HARBOR CAPITAL ADVISORS, INC. Sells 269 Shares of Ascendis Pharma AS (ASND)
Summary HARBOR CAPITAL ADVISORS, INC. reduced its stake in Ascendis Pharma AS (ASND) by 1.17%, selling 269 shares and holding 22,734 shares valued at a
01/19 02:10 EST - defenseworld.net
Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Buy” by Brokerages
Shares of Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eighteen brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, fifteen have given a buy rating...
Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Buy” by Brokerages
Shares of Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eighteen brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, fifteen have given a buy rating...
01/14 07:15 EST - zacks.com
Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Market News
×
Loading news…